Abstract
Importance Standard cardiovascular risk scores fail to predict a substantial fraction of incident vascular clinical events in the general population. Whether circulating neurofilament light chain (NfL), a blood-based biomarker of neuronal axonal injury, independently predicts major cardiovascular or cerebrovascular disease outcomes in adults without known baseline clinical disease has not been tested.
Objective To determine whether plasma NfL is independently associated with incident cardiac and brain vascular events in community-recruited adults and whether it adds prognostic information beyond established clinical risk factors.
Design, Setting, and Participants Prospective cohort analysis within the UK Biobank. Plasma NfL was quantified using the Olink Explore proximity extension assay in 50,043 adults aged 40–69 years at recruitment. After excluding 3,914 participants with baseline known disease, the primary analysis included 46,129 adults. Incident events were ascertained via registry linkage over a median follow-up of 9.6 years.
Exposures Plasma NfL, quantified in Olink Normalized Protein eXpression (NPX) units.
Main Outcomes and Measures Primary outcome: major cardiovascular event (MVE), defined as the composite of cardiovascular death, nonfatal stroke, and nonfatal MI. Secondary outcomes: individual MVE components, heart failure hospitalization, and all-cause mortality.
Results Among 46,129 participants free of baseline disease diagnoses, there were 2,912 incident MVE events. After adjustment for age, sex, BMI, smoking, hypertension, diabetes, and renal function, each one-NPX-unit increase in NfL was independently associated with MVE (aHR 1.46 (95% CI 1.36–1.57; P < .001)), nonfatal stroke (aHR 1.38 (95% CI 1.22–1.57; P < .001)), MI (aHR 1.35 (95% CI 1.22–1.50; P < .001)), cardiovascular death (aHR 1.79 (95% CI 1.59–2.01; P < .001)), heart failure hospitalization (aHR 1.50 (95% CI 1.36–1.65; P < .001)), and all-cause mortality (aHR 1.21 (95% CI 1.18–1.25; P < .001)). The associations were log-linear with no evidence of a threshold or saturation effect. Results were consistent in a sensitivity analysis including the full cohort with baseline vascular disease diagnoses. Addition of NfL to traditional risk factors improved 10-year discrimination most for cardiovascular death (C-statistic 0.809 to 0.817; ΔC = 0.007), heart failure (ΔC = 0.006), and stroke (ΔC = 0.008), with a smaller increment for the MVE composite.
Conclusions and Relevance Plasma NfL was independently associated with incident cardiovascular and cerebrovascular outcomes among community-recruited adults after comprehensive risk-factor adjustments. These findings suggest that blood NfL levels may serve as a biomarker of subclinical vascular disease, strengthening early detection efforts and prompting further diagnostic evaluation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was recieved.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank study received ethical approval from the North West Multi-Centre Research Ethics Committee (reference 06/MRE08/65), and all participants provided written informed consent. The present analysis was conducted under UK Biobank application number 21234 and complied with all relevant institutional and regulatory guidelines.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the UK Biobank. Restrictions apply to the availability of these data, which were used under application number 21234, and so are not publicly available. Data are, however, available from the UK Biobank upon reasonable request and with appropriate approvals (www.ukbiobank.ac.uk).
